Development of prognostic nomograms using institutional data for patients with triple-negative breast cancer

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive disease. Nomograms can predict prognosis of patients with TNBC. Methods: A total of 745 eligible TNBC patients were recruited and randomly divided into training and validation groups. Endpoints were disease-free survival and overall survival. Concordance index, area under the curve and calibration curves were used to analyze the predictive accuracy and discriminative ability of nomograms. Results: Based on the training cohort, neutrophil-to-lymphocyte ratio, positive lymph nodes, tumor size and tumor-infiltrating lymphocytes were used to construct a nomogram for disease-free survival. In addition, age was added to the overall survival nomogram. Conclusion: The current study developed and validated well-calibrated nomograms for predicting disease-free survival and overall survival in patients with TNBC.

A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer

“… 11 , 21 Most of the prediction models were based on the prediction of overall survival (OS) and LMSS for patients with de novo BCLM, 23 , 37 – 39 and the prediction accuracy was higher than that of the seventh version American Joint Committee on Cancer (AJCC)-TNM staging system. 12 , 23 Li et al created a risk evaluation tool to predict the OS of patients with MBC using a nomogram prediction model for the prognosis of LM similar to brain metastases. 40 This study considered the clinicopathological characteristics as actual data on the potential risk of LM in female patients with N + Luminal B (HER2−) BC in China.…”

“…A nomogram, which provides an individualized assessment of risk, is an easy-to-use tool that can be useful to patients and doctors for predicting risk, and for individualized treatment planning decisions for patients and their families, follow-up, and prognosis. 11 , 12 …”

“…A nomogram, which provides an individualized assessment of risk, is an easy-to-use tool that can be useful to patients and doctors for predicting risk, and for individualized treatment planning decisions for patients and their families, follow-up, and prognosis. 11,12 The current treatment and prognosis vary according to the patient prognostic factors, including hormone receptor (HR), HER2, age at diagnosis, tumor size (T), and lymph node status (N), as well as certain molecular markers. [13][14][15] Traditionally, adjuvant chemotherapy and endocrine therapy (ET) or radiotherapy were considered the main postoperative treatment regimens for patients with Luminal B (HER2−) BC, which had a lower pathological complete response rate.…”